Edition:
India

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

2.55USD
19 Jan 2018
Change (% chg)

-- (--)
Prev Close
$2.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
481,284
52-wk High
$2.87
52-wk Low
$1.30

Select another date:

Fri, Jan 5 2018

BRIEF-Idera Pharmaceuticals Provides 2018 Update And Outlook

* IDERA PHARMACEUTICALS - ANTICIPATES CURRENT CASH POSITION CAPABLE OF FUNDING OPERATIONS INTO Q2 2019 Source text for Eikon: Further company coverage:

BRIEF-U.S. FDA Grants Fast Track Designation For Idera Pharmaceuticals’ IMO-2125 In Combination With Ipilimumab

* U.S. FDA GRANTS FAST TRACK DESIGNATION FOR IDERA PHARMACEUTICALS’ IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR TREATMENT OF PD-1 REFRACTORY METASTATIC MELANOMA Source text for Eikon: Further company coverage:

BRIEF-Idera Pharmaceuticals presents positive translational and clinical data update from ongoing IMO-2125 development program

* Idera Pharmaceuticals Inc presents positive translational and clinical data update from ongoing IMO-2125 development program at the 2017 society for immunotherapy of cancer annual meeting (SITC)

BRIEF-Idera Pharmaceuticals reports Q3 loss per share $0.10

* Idera Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

BRIEF-Idera Pharma announces pricing of public offering of common stock

* Idera Pharmaceuticals announces pricing of public offering of common stock

BRIEF-Idera Pharmaceuticals provides corporate governance update

* Idera Pharmaceuticals provides corporate governance update Source text for Eikon: Further company coverage:

BRIEF-Idera Pharmaceuticals announces proposed public offering of common stock

* Idera Pharmaceuticals announces proposed public offering of common stock

BRIEF-Idera Pharmaceuticals files for‍​ mixed shelf

* Idera pharmaceuticals inc files for‍​ mixed shelf of up to $250 million - sec filing‍​ Source text for Eikon: Further company coverage:

BRIEF-Idera Pharmaceuticals Q2 loss per share $0.14

* Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

Select another date: